Table 5.
Risk of acute kidney injury associated with principal components in critically ill COVID-19 patients.
| Principal Component | Unadjusted OR (95% CI) | p | Adjusted OR (95% CI) * | p |
|---|---|---|---|---|
| Day 1 | ||||
| PC-1: IFN-α; EGF |
0.5 (0.23–1.11) | 0.08 | 0.24 (0.07–0.78) | 0.01 |
| PC-2: IL-1R; G-CSF; IP-10; IL-5 |
7.14 (0.58–87.78) | 0.12 | 15.95 (0.31–817) | 0.16 |
| PC-3: IL-10 |
0.45 (0.13–1.51) | 0.19 | - | - |
| PC-4: IL-12; MIP-1β |
7.38 (0.95–57.18) | 0.05 | 51.09 (2.12–1233) | 0.01 |
| PC-5: HGF; MCP-1; IL-6 |
0.39 (0.12–1.22) | 0.10 | - | - |
| Day 5 | ||||
| PC-1: IFN-α; EGF |
0.37 (0.14–0.97) | 0.04 | 0.09 (0.01–0.74) | 0.02 |
| PC-2: IL-1R; G-CSF; IP-10; IL-5 |
1.81 (0.64–5.13) | 0.26 | 7.7 (1.06–55.74) | 0.04 |
| PC-3: IL-10 |
6.46 (0.72–58.29) | 0.09 | - | - |
| PC-4: IL-12; MIP-1β |
0.42 (0.11–1.57) | 0.19 | 0.2 (0.02–1.73) | 0.14 |
| PC-5: HGF; MCP-1; IL-6 |
1.13 (0.41–3.12) | 0.81 | 9.37 (0.97–90.1) | 0.05 |
Principal component (PC); odds ratio (OR); confidence interval (CI); interferon alpha (IFN-α); epidermal growth factor (EGF); interleukin (IL); IL-1 receptor (IL-1R); granulocyte colony-stimulating factor (G-CSF); interferon-gamma-inducible protein 10 (IP-10); macrophage inflammatory protein-1 beta (MIP-1β); hepatocyte growth factor (HGF). Bold values denote statistical significance at the p ≤ 0.05 level. * Adjusted for age and sex.